Smallcapnewsalert

Bright Mountain Media Appoints Elaine Riddell as Non-Executive Director Bringing 15 Years of Experience Driving Transformative Growth

Boca Raton, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) ("Bright Mountain" or the "Company"), a global marketing services platform with current investments in digital publishing, advertising technology, consumer insights, and creative and media services, announced via a FORM-3 1 on August 14, 2024, that they have appointed Elaine Riddell as Non-Executive Director of the Governance Committee.

Elaine Riddell is a dynamic growth strategist with a proven track record of unlocking breakthrough potential within companies. With over 15 years as a CEO at leading firms such as NOPWorld Health (a unit of UBM), TNS Healthcare, and Kantar Health (now Oracle LifeSciences), Elaine has a distinguished history of transforming established global data, analytics, and consulting firms into high-performing market leaders. Her efforts have consistently driven revenue growth at three times the market rate, demonstrating her unique ability to scale businesses rapidly while achieving attractive margins.

Elaine’s expertise extends from her foundational roles at Abbott Labs (now AbbVie) and IMS Health (now IQVIA), where she honed her skills in customer-centric innovation, strategic mergers and acquisitions, and building high-performance cultures. This broad experience underpins her current role as Managing Director at Oaklins DeSilva+Phillips, a leading investment bank specializing in M&A advisory within the marketing and media services sectors.

In addition to her advisory work, Elaine is an influential board director for the Executive Forum, a network of top executives dedicated to advancing business growth. She served as Vice President from 2012-2016 and 2018-2024 and was Chair of the Advisory Board for Themis Analytics from 2016 to its acquisition in 2017. Themis, a leader in data and analytics for the biopharma industry, benefited greatly from Elaine’s strategic guidance.

Elaine is a McGill University alumna and holds dual Canadian and American citizenship.

Elaine Riddell stated, "I am thrilled to join Bright Mountain Media's Board of Directors at an important and exciting time. The company's innovative marketing services approach and commitment to excellence align perfectly with my values and experience. I look forward to working with the team to enhance Bright Mountain Media's governance further and drive its continued success."

Matt Drinkwater, CEO of Bright Mountain Media, commented, "We are excited to welcome Elaine Riddell to our Board of Directors. Her extensive experience transforming market research companies and deep understanding of strategic growth make her an invaluable addition to our team. Elaine's insights and leadership will be instrumental as we advance our position in the global marketing services landscape and uphold our commitment to exceptional governance."

Additionally, Bright Mountain Media is excited to announce that Matt Drinkwater, our Chief Executive Officer, has been appointed Interim Chairman of the Board, effective immediately. This appointment comes at a crucial juncture as we undergo significant strategic and financial transformations. Key developments include:

Strategic Acquisitions: We have undertaken acquisitions that strengthen our market position and expand our capabilities.
Debt Restructuring: Our debt restructuring efforts pave the way for clearer profitability.
Governance Enhancements: We have implemented new governance structures to support our evolving business needs better.
Growth and Transformation: We are advancing our growth strategy and business transformation initiatives to ensure long-term success.
Matt Drinkwater's new role as Interim Chairman highlights our commitment to steering this transformative phase with solid leadership and a clear strategic vision.

About Bright Mountain Media, Inc.

Bright Mountain unites a diverse portfolio of companies to deliver a full spectrum of advertising, marketing, technology, and media services under one roof—fused together by data-driven insights. Bright Mountain's brands include Big Village, Deep Focus, Wild Sky Media, and BrightStream. For more information, please visit www.brightmountainmedia.com.

Forward-Looking Statements for Bright Mountain Media, Inc.

This press release contains certain forward-looking statements that are based on current expectations and involve certain risks and uncertainties. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes," and similar words. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to expectations of our ability to successfully integrate acquisitions, and the realization of any expected benefits from such acquisitions. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in Bright Mountain’s Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Bright Mountain does not undertake any duty to update any forward-looking statements except as may be required by law.

Contact / Investor Relations:
Douglas Baker at [email protected]
561 807-6350
https://otcprgroup.com/

1 https://www.otcmarkets.com/filing/html?id=17760658&guid=S6O-kFYK1gJjJth



Read more: https://otcprgroup.com/

GDC Launches TikTok Account to Share Latest AI-Related News and Trends

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GD Culture Group Limited (“GDC” or the “Company”) (Nasdaq: GDC), along with its subsidiary, AI Catalysis Corp. (“AI Catalysis”), announced today the launch of its TikTok account, . This account is dedicated to disseminating the most current updates, insights, and trends in the world of artificial intelligence. It serves as both an educational and entertainment hub for those keen on staying informed in the swiftly evolving Artificial Intelligence (“AI”) landscape.

As AI is transforming industries and integrating into daily life, the demand for accessible and engaging content about this technology is at an all-time high and growing further. Recognizing and enthusiastic about this attractive trend, GDC is leveraging TikTok’s short-form video format to break down and simplify complex AI topics into easily digestible content. The account will feature a mix of explainer videos, trend analyses, news highlights, and even behind-the-scenes looks at the latest AI innovations.

“Our goal is to demystify AI and make this powerful technology more approachable for everyone,” said Mr. Xiaojian Wang, Chairman and Chief Executive Officer of the Company. “By using TikTok, we can reach a broader audience and engage more into meaningful and inspiring conversations about AI, from industry veterans to curious beginners.”

Content on the account will be regularly updated, covering everything from breakthroughs in machine learning to the latest AI applications and tools, along with real-world case studies showcasing AI in action. As the Company persists in innovating and advancing in the AI domain, this new TikTok channel will play a vital role in sharing knowledge and fostering community.
For more information, follow on TikTok or visit the channel directly at https://www.tiktok.com/ .

About GD Culture Group Limited
GD Culture Group Limited (the “Company”) (Nasdaq: GDC), is a Nevada company currently conducting business mainly through its subsidiaries, AI Catalysis Corp. (“AI Catalysis”) and Shanghai Xianzhui Technology Co, Ltd. The company plans to enter into the livestreaming market with focus on e-commerce and livestreaming interactive games through its wholly owned U.S. subsidiary, AI Catalysis, a Nevada corporation incorporated in May 2023. The Company’s main businesses include AI-driven digital human technology, live-streaming e-commerce business and live streaming interactive game. For more information, please visit the Company's website at https://www.gdculturegroup.com/ .
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.


https://otcprgroup.com/

https://smallcapstockpick.com/gdc-launches-tiktok-account-to-share-latest-ai-related-news-and-trends/

GDC Launches TikTok Account to Share Latest AI-Related News and Trends - SmallCapStockPick GDC Launches TikTok Account to Share Latest AI-Related News and Trends. This account is dedicated to disseminating the most current updates

Bright Mountain Media, Inc Announces Second Quarter 2024 Financial Results

Second quarter revenue increased to $13.0 million compared to $12.6 million for the second quarter of 2023 .

Half year revenue increased by $11.3 million to $25.5 million compared to $14.1 million for the same period of 2023 .

Boca Raton, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a global marketing service platform with capabilities in digital publishing, advertising technology, consumer insights, creative and media services , today announced its financial results for the second quarter and six months ended June 30, 2024.

Matt Drinkwater, CEO of Bright Mountain, expressed enthusiasm about the company's recent credit amendment. “We're pleased with a key amendment we entered into in the second quarter that enhances our financial flexibility by deferring certain payments owed to Centre Lane Partners, our lending partner. This adjustment will help bolster our growth initiatives.

We're also pleased with our ongoing financial performance, marked by the successful integration of Big Village and Deep Focus with our legacy Bright Mountain business, and significant cost-reduction efforts. Our current focus is on unlocking further synergies, launching innovative products and business lines, and advancing our vision of an AI-driven marketing services platform.

An excellent example of these synergies is the organic growth from our ad tech division, driven by the strategic use of data assets from our market research division. This approach opens up new and innovative opportunities to enhance return on advertising spend for our clients. We are optimistic about the potential for future synergies and continued success.”


https://otcprgroup.com/

Read More: https://brightmountainmedia.com/2024/05/17/bright-mountain-media-inc-announces-first-quarter-2024-financial-results/

Bright Mountain Media, Inc Announces First Quarter 2024 Financial Results - Bright Mountain Media Boca Raton, FL, May 14, 2024 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a global holding company with current investments in digital publishing, advertising technology, consumer insights, and creative media services, today announced i...

Microsoft and Lumen Technologies partner to power the future of AI and enable digital transformation to benefit hundreds of millions of customers

PR Newswire

Lumen's Private Connectivity Fabric℠ expands Microsoft's network capacity and capability to support rising demand on datacenters.
Microsoft Azure to further accelerate Lumen's enterprise-wide digital transformation and drive AI initiatives across the organization and save tens of millions of dollars.
DENVER and REDMOND, Wash. , July 24, 2024 /PRNewswire/ -- Today, Lumen Technologies (NYSE: LUMN) and Microsoft Corp . (NASDAQ: MSFT) announced a new strategic partnership that will use the Microsoft Cloud to further drive Lumen's digital transformation. In addition, Microsoft has chosen Lumen to expand its network capacity and capability to meet the growing demand on its datacenters due to AI.

Microsoft and Lumen Technologies partner to power the future of AI.

A network for the AI era

Datacenters have become critical infrastructure that power the compute capabilities for the millions of people and organizations who rely on and trust the Microsoft Cloud. Microsoft is playing the leading role in ushering in the era of AI, offering tools and platforms like Azure OpenAI Service, Microsoft Copilot and others to help people be more creative, more productive and to help solve some of humanity's biggest challenges. As Microsoft continues to evolve and scale its ecosystem, it is turning to Lumen as a strategic supplier for its network infrastructure needs and is investing with Lumen to support its next generation of applications for Microsoft platform customers worldwide.

Lumen's Private Connectivity Fabric℠ is a custom network that includes dedicated access to existing fiber in the Lumen network, the installation of new fiber on existing and new routes, and the use of Lumen's new digital services. This AI-ready infrastructure will strengthen the connectivity capabilities between Microsoft's datacenters by providing the network capacity, performance, stability and speed that customers need as data demands increase.

"AI is reshaping our daily lives and fundamentally changing how businesses operate," said Erin Chapple , corporate vice president of Azure Core Product and Design, Microsoft. "We are focused both on the impact and opportunity for customers relative to AI today, and a generation ahead when it comes to our network infrastructure. Lumen has the network infrastructure and the digital capabilities needed to help support Azure's mission in creating a reliable and scalable platform that supports the breadth of customer workloads—from general purpose and mission-critical, to cloud-native, high-performance computing, and AI, plus what's on the horizon. Our work with Lumen is emblematic of our investments in our own cloud infrastructure, which delivers for today and for the long term to empower every person and every organization on the planet to achieve more."

"We are preparing for a future where AI is the driving force of innovation and growth, and where a powerful network infrastructure is essential for companies to thrive," said Kate Johnson , president and CEO, Lumen Technologies. "Microsoft has an ambitious vision for AI and this level of innovation requires a network that can make it reality. Lumen's expansive network meets this challenge, with unique routes, unmatched coverage, and a digital platform built to give companies the flexibility, access and security they need to create an AI-enabled world."

Accelerating growth through innovation and partnership

Lumen has launched an enterprise-wide transformation to simplify and optimize its operations. By embracing Microsoft's cloud and AI technology, Lumen can reduce its overall technology costs, remove legacy systems and silos, improve its offerings, and create new solutions for its global customer base. Lumen will migrate and modernize its workloads to Microsoft Azure, use Microsoft Entra solutions to safeguard access and prevent identity attacks and partner with Microsoft to create and deliver new telecom industry-specific solutions. This element alone is expected to improve Lumen's cash flow by more than $20 million over the next 12 months while also improving the company's customer experience.

"Azure's advanced global infrastructure helps customers and partners quickly adapt to changing economic conditions, accelerate technology innovation, and transform their business with AI," said Chapple. "We are committed to partnering with Lumen to help deliver on their transformation goals, reimagine cloud connectivity and AI synergies, drive business growth, and help customers achieve more."

This collaboration expands upon the longstanding relationship between Lumen Technologies and Microsoft. The companies have worked together for several years, with Lumen leveraging Copilot to automate routine tasks and reduce employee workloads and enhance Microsoft Teams .

About Lumen Technologies
Lumen connects the world. We are igniting business growth by connecting people, data, and applications – quickly, securely, and effortlessly. Everything we do at Lumen takes advantage of our network strength. From metro connectivity to long-haul data transport to our edge cloud, security, and managed service capabilities, we meet our customers' needs today and as they build for tomorrow. For news and insights visit news.lumen.com , LinkedIn: /lumentechnologies , Twitter: , Facebook: /lumentechnologies , Instagram: and YouTube: /lumentechnologies .

About Microsoft
Microsoft (Nasdaq "MSFT" ) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.

SOURCE Lumen Technologies


https://otcprgroup.com/

https://smallcapnewsalert.com/microsoft-and-lumen-technologies-partner-to-power-the-future-of-ai-and-enable-digital-transformation-to-benefit-hundreds-of-millions-of-customers/

Microsoft and Lumen Technologies partner to power the future of AI and enable digital transformation to benefit hundreds of millions of customers - SmallCapNewsAlert Microsoft and Lumen Technologies partner to power the future of AI and enable digital transformation to benefit hundreds of millions of customers

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog

MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.

Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders. The new preclinical study results announced today are the latest in a string of positive research developments which are progressing MIRA's goal of submitting an Investigational New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ketamir-2 later this year.

Mechanism of Action: Selective NMDA Inhibition

The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the P*P-binding site of the NMDA complex. Ketamir-2 has a 30-50-fold lower affinity to the P*P site compared with ketamine. The lower affinity is important because at high affinity, compounds may affect neurobehavioral functions, potentially leading to side effects such as dissociation and hallucinations. Unlike traditional ketamine, which also affects several other sites on the NMDA receptor and interacts with opioid receptors, dopamine and serotonin transporters, and various acetylcholine receptors, Ketamir-2 exhibits unique selectivity and does not interact with these additional receptor sites. This selectivity is notable as it may contribute to a distinct pharmacological profile for Ketamir-2, potentially reducing the risk of side effects associated with these other interactions.

The potential benefits of Ketamir-2's selective binding also include:

1. Reduced Side Effects: By targeting only the NMDA receptor at the P*P-binding site, Ketamir-2 appears to avoid the broader spectrum of ketamine interactions with other receptors and transporters. This specificity may help minimize unwanted side effects, such as dissociation, hallucinations, and addictive potential, often observed with ketamine use.

2. Improved Safety Profile: The selective inhibition allows for a cleaner pharmacological profile, potentially leading to better tolerability and fewer adverse reactions in patients. These advantages could enhance patient compliance and overall treatment outcomes.

3. Enhanced Therapeutic Effectiveness: With a selective mechanism of action, Ketamir-2 could potentially deliver more consistent and predictable therapeutic effects, which may be particularly beneficial in treating conditions like depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).

Enhanced Safety Profile

Complementing its novel mechanism, recently conducted toxicology studies in rats and dogs have shown no toxicity at very high doses of Ketamir-2. These findings underscore Ketamir-2's excellent safety margin, further supported by its pronounced antidepressant and anxiolytic activities observed at oral doses five to tenfold lower than those tested in the toxicology studies. The substantial therapeutic window of Ketamir-2 offers promising potential for safe and effective use in human therapies.

Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals, commented "During the course of this year, working with our research partners, we continue to discover and report on very promising attributes of Ketamir-2 that we hope will, collectively, enable our IND for this compound. These most recent insights into Ketamir-2's mechanism of action and safety profile mark a significant milestone in our preclinical development program. The novel selectivity and robust safety data bolster our confidence in Ketamir-2's potential as a transformative treatment for neurological and neuropsychiatric disorders. We are excited to advance this compound towards clinical trials, aiming to address the unmet needs of patients suffering from conditions such as depression, TRD and PTSD."

Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals, added, "The ability of Ketamir-2 to selectively inhibit a single specific site at the NMDA receptor complex without affecting other sites is a remarkable finding. Combined with its strong safety profile and pronounced therapeutic effects, we believe that Ketamir-2 holds great promise as a groundbreaking treatment for mental health disorders. We look forward to continuing our IND enabling studies and our progression towards an IND for Ketamir-2."

Preclinical Progress and Future Plans

The additional data announced today builds on previous findings highlighting Ketamir-2's superior brain pe*******on and bioavailability. Unlike traditional ketamine, Ketamir-2 is not a substrate for P-glycoprotein (P-gp), a membrane protein that pumps drugs out of cells, including those in the brain. This characteristic may allow Ketamir-2 to pe*****te the blood-brain barrier more effectively, enhancing its therapeutic potential.

If MIRA's IND is granted by the FDA, it would pave the way for human clinical trials, bringing Ketamir-2 one step closer to becoming a new standard of care for neurological and neuropsychiatric disorders.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations.

In addition, MIRA's novel oral pharmaceutical ma*****na analog, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. The U.S. Drug Enforcement Administration's scientific review of MIRA-55 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations. Additional information about the Company is available at: www.mirapharmaceuticals.com

Ketamir-2 and MIRA-55 are in early-stage preclinical development. There is no assurance that the products will proceed through development or will receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.


https://otcprgroup.com/

https://smallcapnewsalert.com/mira-pharmaceuticals-announces-positive-discovery-of-ketamir-2s-selective-nmda-binding-mechanism-of-action/

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action - SmallCapNewsAlert MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit

The Device and CMC Development Master Plan is designed to support IND-enabling studies

SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.
Resyca is a joint venture between Bespak Group and Medspray Pharma BV which manufactures the formulation-specific microchip-based spray system chosen by Silo for its lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

“The patented nasal spray system uses cutting-edge nose-to-brain drug dispersion, a delivery method that transports the molecules to the brain directly, bypassing the blood-brain barrier,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “For SPC-15, we believe this delivery method could increase the drug’s concentration in the brain to deliver a faster onset of therapeutic benefit and optimized safety for PTSD patients.”

This Device and CMC Development Master Plan is intended to support the development, clinical formulation, and stability of a previously announced investigational new drug (IND)-enabling, large animal GLP (Good Laboratory Practice) study of SPC-15. As part of an existing exclusive license agreement with Medspray Pharma BV, one of joint venture members of Resyca BV, Silo holds exclusive rights to Medspray’s spray mist technology for use with multiple indications including PTSD.

Silo is currently conducting a GLP-compliant pharmacokinetic and pharmacodynamic studies and recently submitted a pre-IND briefing package and meeting request to the U.S. Food and Drug Administration (FDA) for SPC-15. The studies are the final steps required before submission of an IND application to the FDA with the goal of starting its first in human clinical trial.

About SPC-15
SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University and was granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide.

About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information, visit www.silopharma.com and connect on social media at LinkedIn , X , and Facebook .

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.


https://otcprgroup.com/

https://smallcapstockpick.com/silo-pharma-and-resyca-bv.../

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 - SmallCapStockPick Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15. Nose-to-Brain Drug Delivery